Recent studies into retatrutide, a dual stimulant for GLP-1 and GIP receptors, are revealing significant outcomes in addressing obesity and diabetes 2 disease. Preclinical evidence suggest a distinct action https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/